Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667927 · ClinicalTrials.gov registry record · Phase 1
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00667927 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 17 participants.
The verdict
NCT00667927, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Mesna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1991-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667927
The ClinicalTrials.gov registry entry for NCT00667927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00667927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667927 about?
NCT00667927 is a clinical study titled "Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission". This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).
What is the current status of trial NCT00667927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 1991-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00667927?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Mesna (DRUG).
Who is sponsoring clinical trial NCT00667927?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.